141 related articles for article (PubMed ID: 22104154)
1. Predictive value of serum bone sialoprotein in patients with bone metastasis of non-small cell lung cancer.
He JJ; Zhi K; Liu GF
Onkologie; 2011; 34(11):584-8. PubMed ID: 22104154
[TBL] [Abstract][Full Text] [Related]
2. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study.
Papotti M; Kalebic T; Volante M; Chiusa L; Bacillo E; Cappia S; Lausi P; Novello S; Borasio P; Scagliotti GV
J Clin Oncol; 2006 Oct; 24(30):4818-24. PubMed ID: 17050866
[TBL] [Abstract][Full Text] [Related]
3. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
5. Serum bone sialoprotein levels and bone metastases.
Uccello M; Malaguarnera G; Vacante M; Motta M
J Cancer Res Ther; 2011; 7(2):115-9. PubMed ID: 21768695
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of serum bone sialoprotein and prostate-specific antigen doubling time in patients with bone metastasis of prostate cancer.
Wang Y; Zhang XF; Dai J; Zheng YC; Zhang MG; He JJ
J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):559-562. PubMed ID: 23904377
[TBL] [Abstract][Full Text] [Related]
7. Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.
Zhang L; Hou X; Lu S; Rao H; Hou J; Luo R; Huang H; Zhao H; Jian H; Chen Z; Liao M; Wang X
Lung Cancer; 2010 Jan; 67(1):114-9. PubMed ID: 19376608
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis value of serum B7-H3 expression in non-small cell lung cancer.
Zhang G; Xu Y; Lu X; Huang H; Zhou Y; Lu B; Zhang X
Lung Cancer; 2009 Nov; 66(2):245-9. PubMed ID: 19269710
[TBL] [Abstract][Full Text] [Related]
10. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.
Bae HM; Lee SH; Kim TM; Kim DW; Yang SC; Wu HG; Kim YW; Heo DS
Lung Cancer; 2012 Sep; 77(3):572-7. PubMed ID: 22672969
[TBL] [Abstract][Full Text] [Related]
12. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer.
Chang YS; Kim HJ; Chang J; Ahn CM; Kim SK; Kim SK
Lung Cancer; 2007 Sep; 57(3):373-80. PubMed ID: 17513004
[TBL] [Abstract][Full Text] [Related]
13. [Lung cancer in women: clinical features and factors related to survival].
Sen E; Kaya A; Erol S; Savas I; Gonullu U
Tuberk Toraks; 2008; 56(3):266-74. PubMed ID: 18932027
[TBL] [Abstract][Full Text] [Related]
14. Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients.
Rinewalt D; Shersher DD; Daly S; Fhied C; Basu S; Mahon B; Hong E; Chmielewski G; Liptay MJ; Borgia JA
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1344-50; discussion 1350-1. PubMed ID: 22982029
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
Han JY; Choi BG; Choi JY; Lee SY; Ju SY
Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
[TBL] [Abstract][Full Text] [Related]
16. Serum endothelial monocyte-activating polypeptide-II: a novel biomarker in patients with non-small-cell lung cancer.
Sen E; Ulger F; Kaya A; Akar N; Gonullu U
Clin Lung Cancer; 2008 May; 9(3):166-70. PubMed ID: 18621627
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
18. Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer.
Park JH; Choi H; Kim YB; Kim YS; Sheen SS; Choi JH; Lee HL; Lee KS; Chung WY; Lee S; Park KJ; Hwang SC; Lee KB; Park KJ
Lung Cancer; 2009 Dec; 66(3):359-64. PubMed ID: 19339077
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer.
Wang ZX; Bian HB; Wang JR; Cheng ZX; Wang KM; De W
J Surg Oncol; 2011 Dec; 104(7):847-51. PubMed ID: 21721011
[TBL] [Abstract][Full Text] [Related]
20. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
